Therapeutic Areas

Survey data shows individuals are not informed on how COVID-19 could affect their conditions.

Developing new pathways to overcome study-related challenges is key to realizing the promise of the latest gene therapies.

How partnering with a CRO that has experience in both dermatology and innovative trial approaches can help sponsors differentiate their studies and facilitate recruitment.

Thousands of trials have been halted as a consequence of the coronavirus pandemic, slowing the pace of scientific progress dramatically.

Today's reality and the hopes of tomorrow of the COVID-19 pandemic—an updated mapping of vaccines authorized by regulatory bodies and those close to it.

Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge.

Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.

Evolving technologies include modification of receptors on T cells to better target tumor microenvironments and minimize off-tumor cross-reactivity.

87% of people surveyed said they had no concerns about a decentralized approach to clinical trials.

Sangamo executives, Melita Sun Jung and Amy Pooler, discuss the future of genomic medicines for autism spectrum disorder.

Exploring the benefits of capturing and integrating molecular biomarker data within clinical trials to build foundations for data assets.

If you are an organization content with patient-centric approaches, you are behind. Today it is about patient-driven drug development.

Moe Alsumidaie sits down with Ping Yeh, CEO and co-founder of StemoniX, to discuss how MicroOrgans will transform preclinical and clinical development in challenging areas like Alzheimer’s.

Newest revelations suggest Risk Assessment Categorization Tools are now becoming therapeutic area-specific, as an oncology-based risk library is now surfacing.

Examining the unique standards and related challenges when assessing the safety and efficacy of cancer immunotherapy candidates.

The ability to diagnose cancer at earlier stages of the disease is constrained by the specificity and mechanics of traditional diagnostic methods. The growing use of liquid biopsy technology may help overcome such barriers and potentially revolutionize cancer research, patient treatment, and survivor care.

Examining the main challenges in designing and executing MS clinical trials and proposing mitigation strategies that may help alleviate these burdens.

To vie for success in the market for dermatologic therapies, companies developing biologics must navigate a series of significant challenges, including patient compliance and safety.

The National Institutes of Health (NIH) focuses on developing strategies that will encourage further research to support safe and effective therapies for pregnant and lactating women.

The Belgian health ministry has decreed that Belgian lung-cancer patients can receive and be reimbursed for immunotherapy treatments.

At the end of April, European Immunization Week will take place celebrating the achievements of immunization in healthcare. However, contemporary sentiments of skepticism threaten to dampen the event.

With sixty million Americans and Europeans diagnosed with one or more of 7,000 defined rare diseases, the availability of treatments has been less than expected.

A new group of collaborators has formed to determine the benefits and risk tradeoffs Parkinson’s disease patients are willing to make for a potential new therapy. Dr. Brett Hauber of RTI Health Solutions spoke to us about the collaborative.

Gene-editing technology has the ability to give oncology researchers an effective treatment option in the fight against cancer. CRISPR-Cas9 is such a technology that is currently being used to study genes in cancer cells.

Functional dyspepsia is noted globally as being a common condition that currently has no specific therapy despite years of research. This condition is in need of an operational definition so that drug development and treatment trials can move forward with a more definitive trial design.

Patients of gastroesophageal reflux disease (GERD) that have been frequently diagnosed, or misdiagnosed, have been dissatisfied with the available treatment. To resolve this issue, industry players must define meaningful endpoints for future trials, incorporate patient reported outcomes, and apply biomarkers.

Cancer therapy has seen progress - not groundbreaking, but improving thanks to the scientific and technological tools at our disposal. This fall offers industry events and trial evaluations that aim to continue this progressive trend toward a breakthrough.

Gastroparesis patients face a series of symptoms for which there is currently a significant void in treatment. With complications and questions aplenty, answers are in high demand as physicians search for suitable medicines to combat this disease.

Eosinophilic esophagitis (EoE) is a rare esophageal condition that currently has no FDA-approved medications resulting in major gaps in treatment. Therefore, the need for better options and opportunities for drug development is apparent.